Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic Leukaemia

NCT06336395 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT06336395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06336395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Lead sponsor
National University Hospital, Singapore
Phase
Phase 2
Overall status
Recruiting
Start date
March 4, 2020
Completion date
March 31, 2030
Enrollment
500 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b lymphoblastic leukemia